Cipher Pharmaceuticals Signs Exclusive License Agreement with Moberg Pharma for Commercialization of MOB-015 for Canada

 Cipher Pharmaceuticals Signs Exclusive License Agreement with Moberg Pharma for Commercialization of MOB-015 for Canada

Cipher Pharmaceuticals Signs Exclusive License Agreement with Moberg Pharma for Commercialization of MOB-015 for Canada

Shots:

  • Moberg to receive $14.6M as upfront and milestone payments of $4.6M for development and regulatory ($0.5M initial payment) and $10M on commercialization of product
  • Moberg will be responsible for manufacturing the product while Cipher will take care of marketing, distribution and sales after completion of P-III trial and registration
  • Moberg’s MOB-015 is a topical formulation of terbinafine, based on non-prescription nail spraying Kerasal Nail/ Emtrix. MOB-015 is currently in P-III (N= approx. 750 – 800), being evaluated in multicentre studies including North America and EU

Click here to read full press release/ article | Ref: Moberg | Image: My news Desk

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post